BioXcel Therapeutics (BTAI) Stock: Buy, Sell, or Hold?
BTAI - BioXcel Therapeutics, Inc. Common Stock
$0.07
-0.04 (-37.11%)
▼
5d:
-59.26%
30d:
-91.1%
90d:
-93.31%
HOLD
MODERATE Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When BTAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BTAI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: BTAI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: BTAI is currently trading at $0.07, which is considered oversold relative to its 30-day fair value range of $0.35 to $1.03.
Technical Outlook: Technically, BTAI is in a strong uptrend. Immediate support is located at $0.07, while resistance sits at $0.83. Short-term momentum is weak, with the stock down 37.1% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $21.50 (+28993.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BTAI is in a strong uptrend. Immediate support is located at $0.07, while resistance sits at $0.83. Short-term momentum is weak, with the stock down 37.1% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $21.50 (+28993.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.35 -
$1.03
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-37.1%)
- BULLISH: Trading 28993.4% below Wall St target ($21.50)
- NEUTRAL: Bottoming setup forming (45/100) — watch for confirmation
- CAUTION: 5-day price weakness (-59.3%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.35 -
$1.03
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.07
Resistance Level
$0.83
Current Trend
Strong Uptrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.03
Wall Street Target
$21.50
(+28993.4%)
Revenue Growth (YoY)
51.7%
Share & Embed Analysis
Last updated: September 12, 2026 2:38 PM ET
Data refreshes hourly during market hours. Next update: 3:38 PM
Data refreshes hourly during market hours. Next update: 3:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BTAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
